KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Net Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Net Margin for 9 consecutive years, with 60.47% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 8084.0% year-over-year to 60.47%, compared with a TTM value of 30.16% through Dec 2025, up 4988.0%, and an annual FY2025 reading of 30.16%, up 4988.0% over the prior year.
  • Net Margin was 60.47% for Q4 2025 at Biocryst Pharmaceuticals, up from 8.09% in the prior quarter.
  • Across five years, Net Margin topped out at 60.47% in Q4 2025 and bottomed at 59.23% in Q4 2023.
  • Average Net Margin over 3 years is 7.74%, with a median of 11.59% recorded in 2024.
  • Peak annual rise in Net Margin hit 8084bps in 2025, while the deepest fall reached 1471bps in 2025.
  • Year by year, Net Margin stood at 59.23% in 2023, then surged by 66bps to 20.37% in 2024, then skyrocketed by 397bps to 60.47% in 2025.
  • Business Quant data shows Net Margin for BCRX at 60.47% in Q4 2025, 8.09% in Q3 2025, and 3.11% in Q2 2025.